



Endothelial dysfunction as an independent risk factor for cardiovascular disease in patients with metabolic syndrome: A prospective study in a tertiary hospital from central India

Premshanker Singh¹, Ritu Karoli², Prafull Kumar Singh³

¹ Former Professor and Head Medicine (MD Medicine), Dr RML Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

² Professor Medicine (MD Medicine), Dr RML Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

³ Senior Resident (MD Medicine), Dr RML Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

Abstract

Background: The objective was to evaluate endothelial dysfunction as an independent risk factor for cardiovascular disease in patients with metabolic syndrome.

Methods: This prospective, cross-sectional, hospital based observational study included 90 patients with metabolic syndrome and 40 age and sex matched controls who attended hypertension clinic, diabetes clinic, general medicine OPD and patients admitted in wards, department of medicine, Dr RML Institute of Medical Sciences, Lucknow India. All patients who fulfilled inclusion criteria were subjected to the color Doppler of the brachial artery in the department of radio- diagnosis of the same institute.

Results: 90 patients with metabolic syndrome included in the study, 44 patients (48.9%) were males and 46 patients (51.1%) were females. Twenty males (45.5%) had a waist circumference of >90 cm whereas 40 females (87%) had waist circumference of >80 cm. 18 males (40.9%) had abnormal waist hip ratio whereas 44 females (95.7%) had abnormal waist hip ratio. 86 patients (95.6%) had a SBP >130 mm of Hg whereas 78 patients (86.7%) had a DBP >85 mm of Hg. 48 patients (53.3%) had impaired fasting blood sugar i.e. >100 mg/dl, 50 patients (55.6%) had a TGL level >150 mg/dl, and 18 males (40.0%) had HDL < 40 mg/dl whereas 36 females (78.3%) had HDL value < 50 mg/dl respectively. The mean brachial artery baseline diameter were 3.51 ± 0.40 mm in males and 3.26 ± 0.30 mm in females respectively, FMD percentage was 14.92 ± 3.56 in females and 14.53 ± 4.02 in males, and GTN mediated dilatation were $27.67 \pm 9.83\%$ in females and $27.62 \pm 6.86\%$ in males respectively.

Conclusion: Estimation of Endothelial Dysfunction in patients at risk of developing full blown Metabolic Syndrome may predict the cardiovascular morbidity and mortality independently in these individuals even before fulfilling the 3/5 criteria of NCEP/ATP III Guidelines for the diagnosis of metabolic syndrome.

Keywords: endothelial dysfunction, metabolic syndrome, cardiovascular disease

Introduction

The vascular endothelium is an important regulatory organ in maintaining of cardiovascular homeostasis. Normal endothelial function includes control over thrombosis and thrombolysis, platelets and leukocyte interaction with the vessel wall, and regulation of vascular tone and smooth muscle cell proliferation. One of the most important regulatory and vasoactive substances produced by endothelial cells is nitric oxide (NO). Nitric oxide modulates vascular tone, and inhibits the interaction between blood cells and the vessel wall. In addition, NO appears to be an endogenous inhibitor of tumor necrosis factor and the expression of proinflammatory molecules, such as the vascular cell adhesion molecule (VCAM-1) and the chemo attractant protein- I [1].

The vascular endothelium is a large paracrine organ that secretes numerous factors regulating vascular tone, cell growth, platelet and leukocyte interactions and thrombogenicity. Endothelial dysfunction (ED) can be defined as the partial or complete loss of balance between vasoconstrictors and vasodilators, growth promoting and inhibiting factors, pro-atherogenic and anti-atherogenic factors, and pro-coagulant and anti-coagulant factors [1].

There are different techniques to evaluate the endothelium functional capacity, that depend on the amount of Nitric

Oxide (NO) produced and the vasodilatation effect. The percentage of vasodilatation with respect to the basal value represents the endothelial functional capacity. Taking into account that shear stress is one of the most important stimulants for the synthesis and release of NO, the non-invasive technique most often used is the transient flow-modulate "endothelium- dependent" post-ischemic vasodilatation, performed on conductance arteries such as the brachial, radial or femoral arteries. This vasodilatation is compared with the vasodilatation produced by drugs that are NO donors, such as nitroglycerin, called "endothelium independent". The vasodilatation is quantified by measuring the arterial diameter with high resolution ultrasonography. Laser- Doppler techniques are now starting to be used that also consider tissue perfusion.

The Metabolic Syndrome represents the co-existence of insulin resistance, hypertension, central adiposity, dyslipidemia, and a pro-inflammatory, pro-thrombotic state. Patients with this syndrome are at increased risk for the development of type 2 diabetes mellitus and cardiovascular disease. Epidemiologic studies reveal a prevalence of the Metabolic Syndrome that increases with age and obesity. Patients with the Metabolic Syndrome should be recognized as being at high risk for cardiovascular complications [2].

Endothelial dysfunction occurs in various states such as Diabetes, Hypertension, Obesity, Hyperlipidemia, Atherosclerosis, Metabolic Syndrome (Insulin resistant states). Brachial artery flow-mediated dilation (FMD) is a validated, widely used method for gauging endothelial dysfunction due to its noninvasive and practical nature, as pointed out in the study by Calermajer *et al.*⁹ Endothelial dysfunction in the brachial artery highly correlates with endothelial dysfunction in the coronary circulation, which is emerging as an independent risk factor for cardiovascular disease. According to Moens *et al*, FMD is diminished in patients with several coronary risk factors, is an independent predictor of cardiovascular events, and improves with risk reduction therapy^[3].

This study is relevant in the Indian context as there is paucity of data regarding endothelial dysfunction in patients with metabolic syndrome in North Indian population moreso in the rural population. Further, this non-invasive evaluation of endothelial dysfunction by means of color Doppler is a cheap, easily available, and reproducible method and it serves as a predictor and marker of future cardiovascular risk and events.

Objective: To evaluate endothelial dysfunction as independent risk factor for cardiovascular disease in patients with metabolic syndrome.

Methods

Subjects

This prospective, cross-sectional and hospital based observational study was carried out in the department of internal medicine, Dr RML Institute of medical sciences Lucknow, UP, India for a period of 02 years wef 01 Dec 2017 to 31 Dec 2019 Ninety patients with Metabolic syndrome and 40 age and sex matched controls were included in the study. The subjects attended hypertension clinic, diabetes clinic, general medicine OPD and patients admitted in wards department of medicine, Dr RML Institute of Medical Sciences, Lucknow, UP, India

Table 1: Clinical identification of metabolic syndrome.

Risk Factor	Defining level
	Waist circumference
Males	≥90 cm
Females	≥80 cm
Serum triglycerides	□ 150 mg/dl
High-density lipoprotein cholesterol	
Males	< 40 mg/dl
Females	< 50 mg/dl
Blood pressure	□ 130/ □ 85 mm Hg
Fasting blood glucose	□ 100 mg/dl

Exclusion Criteria

Hypoglycemia, Diabetic ketoacidosis, Hyperosmolar nonketotic Diabetic coma, Acute myocardial infarction, Cerebrovascular accidents, Acute infections, Chronic kidney disease, Collagen vascular disorders.

Study Design

This is a prospective, cross-sectional study. An informed consent was obtained from each subject prior to entering the study. Clinical examination included blood pressure measurement, cardiovascular examination, ECG, anthropometrical measurements and body-mass index (BMI). Biochemical assessment included fasting blood

sugar (FBS) and post-prandial blood sugar levels, Renal function tests (Blood urea & serum creatinine), urine for microalbumin, and Serum lipid profile. Plasma glucose and lipid estimation were done after an overnight fast of 12 hour.

All patients who fulfilled inclusion criteria were subjected to the color Doppler of the brachial artery in the department of radio-diagnosis of the same institute.

Inclusion Criteria

Patients were included on the basis of NCEP/ATP III guidelines for the metabolic syndrome and IDF criteria for central adiposity in Asian Indian phenotypes (three or more of the followings):

Assessment of Endothelial Dysfunction by Color Doppler of Brachial Artery

The brachial artery was imaged above the antecubital fossa in the longitudinal plane. A segment with clear anterior and posterior intimal interfaces between the lumen and vessel wall was selected for continuous 2D grayscale imaging.

Endothelium-dependent FMD: To create a flow stimulus in the brachial artery, a sphygmomanometric (blood pressure) cuff was first placed above the antecubital fossa. A baseline rest image was acquired, and blood flow was estimated by time-averaging the pulsed Doppler velocity signal obtained from a mid-artery sample volume. Thereafter, arterial occlusion was created by cuff inflation to supra systolic pressure. Typically, the cuff was inflated to at least 50 mmHg above systolic pressure to occlude arterial inflow for a standardized length of time. This causes ischemia and consequent dilation of downstream resistance vessels via autoregulatory mechanisms. Subsequent cuff deflation induced a brief high-flow state through the brachial artery (reactive hyperemia) to accommodate the dilated resistance vessels. The resulting increase in shear stress caused the brachial artery to dilate. The longitudinal image of the artery was recorded continuously from 30 seconds to 2 min after cuff deflation. A mid-artery pulsed Doppler signal was obtained upon immediate cuff release and no later than 15s after cuff deflation to assess hyperemic velocity.

Endothelium-independent vasodilatation with nitroglycerin:

At least 10 min of rest was needed after reactive hyperemia (FMD) before another image was acquired to reflect the re-established baseline conditions. An exogenous NO donor, such as a single high dose (0.4 mg) of nitroglycerin(NTG) spray or sublingual tablet was given to determine the maximum obtainable vasodilator response, and served as a measure of endothelium-independent vasodilatation reflecting vascular smooth muscle function. Peak vasodilatation occurred 3 to 4 min after NTG administration; images should be continuously recorded during this time.

Analysis

Characterizing FMD: Flow-mediated vasodilatation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter. Similarly endothelium independent vasodilatation is calculated. The difference between the two percentages is taken as a marker for Endothelial Dysfunction^[4]. Statistical analysis was performed using SPSS version 14.0 Statistical package for windows (SPSS, Chicago, IL). Paired and students't' test, Multivariate regression analysis was done. p <0.05 was

taken as statistically significant.

Results

In the 45 patients studied 22 (48.9%) were males and 23(51.1%) were females with an age range of 34 to 70 years. Table 1 denotes the demographic profile of patients with metabolic syndrome. Ten males (45.5%) had a waist circumference of >90 cm whereas 20 females (87%) had waist circumference of >80 cm. 9 males (40.9%) had abnormal waist hip ratio whereas 44 females (95.7%) had abnormal waist hip ratio.86 patients (95.6%) had a SBP >130 mm of Hg whereas 48 patients (86.7%) had a DBP >85 mm of Hg. 48 patients (53.3%) had impaired fasting blood sugar i.e. >100 mg/dl, 50 patients (55.6%) had a TGL level >150 mg/dl, and 18 males (40.0%) had HDL < 40 mg/dl whereas 36 females (78.3%) had HDL value < 50 mg/dl respectively.

Table 2: Demographic Profile.

	Mean	Standard Deviation
Age (years)	54.36	10.71
Weight (kg)	72.29	10.6
Height(cm)	160.33	7.39
BMI (kg/m ²)	28.81	5.16
Waist (cm)	100.56	9.06
Hip (cm)	100.82	8.22
Waist hip ratio	0.997	0.035
SBP(mm Hg)	155.82	15.44
DBP(mm Hg)	94.18	9.4
BS (F) (mg%)	118.56	29.57
BU (mg%)	39.91	5.95
SCR (mg %)	0.86	0.28

(SBP-Systolic Blood Pressure, DBP-Diastolic Blood Pressure, BS(F)-Blood Sugar Fasting, TGL-Triglyceride, HDL-High Density Lipoprotein, BMI-Body Mass Index, ED-Endothelial Dysfunction, BU-Blood Urea, LDL-Low Density Lipoprotein, NS-Non Significant.)

Table 3: Carl Pearson’s Product Moment Correlation (r) of Endothelial dysfunction with other variables.

	‘r’	P
SBP	0.338	0.023
DBP	-0.001	NS
BS(F)	0.488	0.002
TGL	0.488	0.001
HDL	-0.656	< 0.001
BMI	0.436	0.003
Waist hip ratio	-0.121	NS
BU	0.385	0.009
LDL	0.477	0.001
Age	0.506	< 0.001

Univariate analysis of different variables with Endothelial Dysfunction was done using Carl Pearson’s Correlation. (Table 3) SBP, BS (F), TGL, HDL, BMI were significantly correlated with ED while DBP and Waist hip ratio were not. Further on comparing the Endothelial dysfunction between cases and controls using T- test, a significant higher percentage was found in the cases as compared to controls.




Fig 1: Distribution of Control and Case Frequencies in relation to Endothelial Dysfunction.

Figure 1 summarizes that there is significant difference between cases and controls and cases are high on the counts of endothelial dysfunction

Stepwise multiple regression analysis

The table (4) illustrates a stepwise multiple regression model with Endothelial Dysfunction as the dependant variable and HDL, fasting blood glucose, SBP, Age and TGL as independent variables. The step wise multivariable predictors of endothelial dysfunction in the present study were high density lipoprotein (HDL), blood sugar fasting (BSF), systolic blood pressure (SBP), age and low density lipoprotein (LDL). HDL was the most important predictor of endothelial dysfunction with 66.4% predictability, 44.1%

variance (R square) and $\square = -0.254$. Only HDL was inversely correlated with endothelial dysfunction where as all other variables were directly associated with endothelial dysfunction (ED).

Table 4: Model summary & coefficient for endothelial dysfunction.

	Variables	R	R Square	\square	95% Confidence Interval	
					Lower	Upper
1	HDL	0.665	0.440	-0.253	-0.028	-0.478
2	BS (F)	0.771	0.594	0.093	0.048	0.136
3	SBP	0.814	0.660	0.176	0.077	0.273
4	Age	0.839	0.704	0.201	0.052	0.312
5	LDL	0.861	0.741	0.104	0.013	0.197

Discussion

Endothelial dysfunction is a harbinger of many cardiovascular diseases. The assessment of endothelial dysfunction is a rational approach for risk assessment of patients with or at risk for cardiovascular disease.⁵ Brachial artery flow-mediated dilation (FMD) is a surrogate marker of endothelial vasodilator function in humans.⁶ Studies demonstrate that endothelial dysfunction precedes the development of clinically apparent atherosclerosis in individuals with CVD risk factors as smoking, hypertension, hyperlipidemia, diabetes mellitus, and obesity^[7, 8, 9]. Treating of risk factors may reverse endothelial dysfunction^[10]. Finally, endothelial dysfunction is a precursor of future CVD events^[11].

Endothelial dysfunction and Dyslipidemia: Asian Indians have hypertriglyceridemia, low HDL-C, and high levels of small-dense low-density lipoprotein (LDL), it characterises insulin resistance and is labelled as 'atherogenic dyslipidemia'^[12].

CAD patients have impaired Endothelial dependent and independent functions, FMD correlates with serum HDL-C levels on univariate and multivariate analysis^[13]. Increased high-density lipoprotein concentration in patients of hypercholesterolemia improves endothelial function^[14]. In our study, serum HDL (a risk factor for CAD) inversely correlated ($r = -0.656$, $p < 0.001$) with ED on multivariate analysis, in unison with prior listed studies. In addition, serum cholesterol and LDL, have been inversely associated with FMD in prior studies, also consistent with the present study^[15].

Endothelial dysfunction and Glucose tolerance

Endothelial dysfunction precedes the vascular manifestations of Diabetes Mellitus. DM leads to endothelial dysfunction by multiple pathways, mostly as a result of insulin resistance^[16].

Obesity, insulin resistance, and endothelial dysfunction are closely linked in the natural history of type 2 diabetes. Visceral fat-derived metabolic products, hormones, and cytokines play a major role in affecting insulin action in skeletal muscle resulting in low-grade inflammation and endothelial dysfunction. Some shared insulin signaling abnormalities in muscle, fat, and endothelial cells may play role in this causation^[17].

In our study, ED correlated directly with impaired fasting glucose ($r = 0.488$, $p < 0.05$) and LDL levels ($r = 0.477$, $p < 0.001$), similar to the study conducted by Clarkson *et al.*^[18]. On stepwise multivariate analysis, age, fasting plasma glucose were important contributing factors for ED in accordance with the study conducted by Caballero *et al.*^[19].

Endothelial dysfunction and Hypertension: Our study provides evidence that SBP is an important correlate of endothelial dysfunction. Indeed, the gradient of diminished FMD begins at non-hypertensive BP levels. A causal relationship, between hypertension and endothelial dysfunction has been observed in earlier studies^[20]. Also non-obese individuals have endothelial dysfunction, suggesting that hypertension causes endothelial dysfunction independent of the effect of weight^[21].

Antihypertensive treatment improves-endothelial function and these patients have fewer future CVD events^[22, 23]. The

causal relationship between endothelial dysfunction and hypertension is not clear. Studies show that endothelial dysfunction may cause essential hypertension^[24]. However, the present cross-sectional study cannot determine whether endothelial dysfunction, is a cause or consequence of hypertension, or alternatively, whether FMD and SBP were associated by virtue of their joint correlation with a third factor, such as arterial stiffness^[25].

Endothelial dysfunction and age: Endothelial function decreases with advancing age, but the mechanisms is unclear and is possibly due to increase in reactive oxygen species production with increasing age^[26, 27, 28]. And in our study, age is significantly correlated to Endothelial Dysfunction.

Endothelial dysfunction and Obesity: Asian Indians have higher proportion of body fat and lower body mass index (BMI), high waist-hip ratio (WHR) with low waist circumference and are leaner and thinner against Caucasians counterparts^[29]. A direct association between BMI and Endothelial Dysfunction was found in our study consistent with earlier studies^[30, 31]. Endothelial Dysfunction improved with weight loss^[32]. The possible causal factors may be oxidative stress and systemic inflammation^[33]. However, we did not find that BMI was a multivariable predictor of ED. A plausible explanation may be that increased body fat and decreased lean body mass may compensate each other not allowing appreciable increase in the value of BMI. This may aptly explain that BMI does not reflect adiposity accurately in Asian Indians.

The most striking finding in our study was the predictability of our covariates on the outcome of Endothelial Dysfunction in Stepwise Multiple Regression Model. HDL was the most significant of all the predictors accounting for 66.4% predictability, 44.1% of the total variance (R square) and $\beta = -0.254$. Only HDL was inversely associated with ED whereas all other variables were directly related to ED. However a larger and further prospective studies are required to strengthen our study findings so that in the future it may be applicable and useful to the masses.

Whereas BMI, blood urea and TGL were associated with impaired ED in univariate analysis, they were not retained in the multivariate regression model. There are several plausible explanations for the apparent dissimilarity with prior research. A reasonable explanation may be that increased body fat and decreased lean body mass may compensate each other and appreciable increase in the value of BMI is negated. The lack of independence of the variables could be attributed to the clustering of hypertension, glucose intolerance, lipid abnormalities, and obesity in individuals with the metabolic syndrome, resulting in colinearity among these variables^[34]. Our study may have potential confounders because of the small sample size and community-based design. Alternatively, it may have been difficult to detect these relations because we studied middle-aged-to-elderly individuals with a typical distribution of lipid and glucose values and relatively low mean FMD% and more ED. Studies show that in the presence of multiple competing risk factors, the combined effect may overwhelm the particular effect of the risk factor^[35, 36, 37].

So large prospective studies are needed to assess the strength of association of brachial artery FMD or other ED

markers with Metabolic syndrome and future cardiovascular events. The present study shows that ED is associated with components of Metabolic Syndrome which is also an independent risk factor for CAD/CVD. Assessment of ED should be included along with other conventional risk variables such as lipoproteins to identify individuals at increased risk for CAD and extended Cardio-metabolic syndrome at an early stage, given the paucity of facilities for invasive evaluation in India.

Conclusion

- Estimation of ED in patients at risk of developing full blown Metabolic Syndrome may predict the cardiovascular morbidity and mortality as independent risk factor for cardiovascular disease in these individuals even before fulfilling the 3/5 criteria of NCEP/ATP III Guidelines for the diagnosis of Metabolic Syndrome.
- We therefore recommend that evaluation of Endothelial Dysfunction by brachial artery flow mediated dilatation (FMD) should be included in the diagnostic criteria of the expanded Cardio-Metabolic Syndrome as other markers like microalbuminuria, apo-lipoprotein \square , Tumour Necrosis Factor (TNF- \square), Interleukin-1 and 6 (IL-1, IL-6).
- Endothelial Dysfunction is a surrogate marker and predictor of pre-Metabolic Syndrome.

Funding

No funding source

Conflict of interest

None

Ethical approval

Approved by Ethical Committee

References

1. Després JP, Brewer HB. Metabolic syndrome: the dysmetabolic state of dysfunctional adipose tissue and insulin resistance. *Eur Heart J*,2008;10(B):B1-3.
2. Gonzalez AS, Guerrero DB, Soto MB, *et al.* Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. *Eur J Clin Nutr*,2006;60:802-9.
3. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. *Circulation*,2007;115:1285-95.
4. Flammer AJ, Luscher TF. Three decades of endothelium research: from the detection of nitric oxide to the everyday implementation of endothelial function measurements in cardiovascular diseases. *Swiss Med Wkly*,2010;140:w13122.
5. Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, *et al.* Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. *Eur Heart J*,2010;31:1142-8.
6. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, *et al.* Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. *N Engl J Med*,1986;315:1046-51.
7. Schachinger V, Britten MB, Zeiber AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. *Circulation*,2000;101:1899-1906.
8. Leung DY, Leung M. Non-invasive/invasive imaging: significance and assessment of coronary microvascular dysfunction. *Heart*,2011;97:587-95.
9. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID *et al.* Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. *Lancet*,1992;40:1111-5.
10. Anderson EA, Mark AL. Flow-mediated and reflex changes in large peripheral artery tone in humans. *Circulation*,1989;79:93-100.
11. Laclaustra M, Frangi AF, Garcia D, Boisrobert L, Frangi AG, Pascual I. Detailed exploration of the endothelium: parameterization of flow-mediated dilation through principal component analysis. *Physiol Meas*,2007;28:301-20.
12. Charakida M, Masi S, Luscher TF, Kastelein JJP, Deanfield JE. Assessment of atherosclerosis: the role of flow-mediated dilatation. *Eur Heart J*,2010;31:2854-61.
13. Al-Qaisi M, Kharbada RK, Mittal TK, Donald AE. Measurement of endothelial function and its clinical utility for cardiovascular risk. *Vasc Health Risk Manag*,2008;4:647-52.
14. Bots ML, Westerink J, Rabelink TJ, De Koning EJP. Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. *Eur Heart J*,2005;26:363-8.
15. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, *et al.* Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. *J Am Coll Cardiol*,2002;39:257-65.
16. Thijssen DHJ, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, *et al.* Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. *Am J Physiol Heart Circ Physiol*,2011;300:H2-12.
17. Palinkas A, Toth E, Vennert L, Rigo F, Csana'dy M, Picano E. Temporal heterogeneity of endothelium-dependent and -independent dilatation of brachial artery in patients with coronary artery disease. *Int J Cardiovasc Imaging*,2002;18:337-42.
18. Frangi AF, Laclaustra M, Lamata P. A registration-based approach to quantify flow-mediated dilation (FMD) of the brachial artery in ultrasound image sequences. *IEEE Trans Med Imaging*,2003;22:1458-69.
19. Sonka M, Liang W, Lauer RM. Automated analysis of brachial ultrasound image sequences: early detection of cardiovascular disease via surrogates of endothelial function. *IEEE Trans Med Imaging*,2002;21:1271-9.
20. Gori T, Parker JD, Munzel T. Flow-mediated constriction: further insight into a new measure of vascular function. *Eur Heart J*,2011;32:784-7.
21. Laclaustra M, Frangi AF, Frangi AG, Casasnovas JA, Cia P. Association of endothelial function and vascular data with LDL-c and HDL-c in a homogeneous population of middle-aged, healthy military men: Evidence for a critical role of optimal lipid levels. *Int J Cardiol*,2008;125:376-82.

22. Halcox JPI, Donald AE, Ellins E, Witte DR, Shipley MJ, Brunner EJ, *et al.* Endothelial function predicts progression of carotid intima-media thickness. *Circulation*,2009;119:1005-12.
23. Gokce N, Keaney Jr JF, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, *et al.* Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. *J Am Coll Cardiol*,2003;41:1769-75.
24. Karatzis EN, Ikonomidis I, Vamvakou GD, Papaioannou TG, Protogerou AD, Andreadou I, *et al.* Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation. *Am J Cardiol*,2006;98:1424-8.
25. Gokce N, Keaney Jr JF, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. *Circulation*,2002;105:1567-72.
26. Zambanini A, Cunningham SL, Parker KH, Khir AW, McG Thom SA, Hughes AD. Wave-energy patterns in carotid, brachial, and radial arteries: a noninvasive approach using wave-intensity analysis. *Am J Physiol Heart Circ Physiol*,2005;289:H270-6.
27. Nelson MR, Stepanek J, Cevette M, Covalciuc M, Hurst RT, Tajik AJ. Noninvasive measurement of central vascular pressures with arterial tonometry: clinical revival of the pulse pressure waveform? *Mayo Clin Proc*,2010;85:460-72.
28. Hayward CS, Kraidly M, Webb CM, Collins P. Assessment of endothelial function using peripheral waveform analysis: a clinical application. *J Am Coll Cardiol*,2002;40:521-8.
29. Rietzschel ER, Boeykens E, De Buyzere ML, Duprez DA, Clement DL. A comparison between systolic and diastolic pulse contour analysis in the evaluation of arterial stiffness. *Hypertension*,2001;37:E15-22.
30. Cavalcante JL, Lima JAC, Redheuil A, Al-Mallah MH. Aortic stiffness: current understanding and future directions. *J Am Coll Cardiol*,2011;57:1511-22.
31. Adji A, Hirata K, O'Rourke MF. Clinical use of indices determined non-invasively from the radial and carotid pressure waveforms. *Blood Press Monit*,2006;11:215-21.
32. Horva' th IG, Ne'meth A, Lenkey Z, Alessandri N, Tufano F, Kis P, *et al.* Invasive validation of a new oscillometric device (Arteriograph) for measuring augmentation index, central blood pressure and aortic pulse wave velocity. *J Hypertens*,2010;28:2068-75.
33. Wassertheurer S, Kropf J, Weber T, Van der Giet M, Baulmann J, Ammer M, *et al.* A new oscillometric method for pulse wave analysis: comparison with a common tonometric method. *J Hum Hypertens*,2010;24:498-504.
34. Sigrist MK, Chiarelli G, Levin A, Romann A, Weber C. Pulse wave velocity measurements are reproducible in multiple trained observers: a short report. *Nephron Clin Pract*,2010;116:c60-4.
35. Van Leeuwen-Segarceanu EM, Tromp WF, Bos W-JW, Vogels OJ, Groothoff JW, Van der Lee JH. Comparison of two instruments measuring carotid-femoral pulse wave velocity: Vicorder versus SphygmoCor. *J Hypertens*,2010;28:1687-91.
36. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature* 1993;362:80-1.
37. Drexler H, Hornig B. Endothelial dysfunction in human disease. *JMO/ Cell Cardiol*,1999;31:51.